Next Generation Cancer Diagnostics Market Expected to Collect $11.04 Billion By 2024: Grand View Research Inc.

Grand View Research, Inc. – Market Research And Consulting.

According to a report,“Next Generation Cancer Diagnostics Market Size & Forecasts By Technology (NGS, LOAC & RT-PCR), By Application (CTC, Biomarker), By Cancer Type (Lung, Breast), By Function Companion Diagnostics), And Trend Analysis, 2018 – 2024”, published by Grand View Research, Inc., the global next generation cancer diagnostics market is anticipated to reach USD 11.04 billion by 2024. Key drivers for this vertical include rising advancement in genomics and proteomics-based research coupled with increasing prevalence of oncology disorders.

Key Takeaways from the report:

• The qPCR & multiplexing segment captured the largest market share in 2015 owing to the presence of a wide product portfolio serving numerous applications in oncology R&D

• Next generation sequencing services and solutions for oncology applications are anticipated to be the fastest growing segment

• Oncology diagnostics in biomarker discovery is expected witness growth as it subsequently facilitates drug designing and identification of novel targets against tumors

• On the basis of cancer type, this vertical is segmented into lung, breast, colorectal, cervical, and other forms of cancer

• Research projects to establish the therapeutic index of anticancer cytotoxic drugs are one of the key factors responsible for expected growth

• North America dominated the market with respect to revenue generation in 2014 due to concerted efforts directed toward the development of next generation sequencing technology and companion diagnostics in personalized medicine

• Some of the key players contributing significantly to the next generation cancer diagnostics market are Novartis AG; Cepheid; Hoffman La Roche Ltd.; PerkinElmer, Inc.; Sysmex Corporation; Abbott; Thermo Fisher Scientific, Inc.; Koninklijke Philips N.V.; Agilent Technologies; Illumina, Inc.; Genomic Health, Inc.; Qiagen; Janssen Global Services, LLC; Hologic, Inc.; Myriad Genetics, Inc.; Almac Group; Opko Health, Inc.; and GE Healthcare.

U.S. Next generation cancer diagnostics market share, by Technology Type, 2013-2024

Browse More Reports in Biotechnology Industry:

• Oligonucleotide Synthesis Market: Continuous rise in usage of oligonucleotide synthesis across various aspects of human health management, from molecular diagnostics to therapeutics, is spurring Oligonucleotide Synthesis Market revenue growth.

• Primary Cell Culture Market: Growth in production of vaccines, monoclonal antibodies, and regenerative medicines, patent expiration of blockbuster biologics, and rising demand for stem cell therapy and tissue engineering are factors promoting the growth of Primary Cell Culture market.

Global next generation cancer diagnostics market, by application, 2015 (USD Million)

Rise in number of oncological research projects to elucidate tumorigenesis and the underlying mechanisms, consequently raising the demand for serial sampling, diagnosis, and therapeutic manipulation, is a growth rendering driver of this market.

Media Contact
Company Name: Grand View Research, Inc.
Contact Person: Sherry James, Corporate Sales Specialist – U.S.A.
Email: Send Email
Phone: 1-415-349-0058, Toll Free: 1-888-202-9519
Address:201, Spear Street, 1100
City: San Francisco
State: California
Country: Switzerland
Website: www.grandviewresearch.com/industry-analysis/next-generation-cancer-diagnostics-market